Author

Ольга Веремчук

Observed names: O. Veremchuk, Olga Veremchuk

Institution: Immatics Biotechnologies (Germany)

Observed institution: Immatics Biotechnologies (Germany)

ORCID: 0000-0003-3298-7076

Observed ORCID: 0000-0003-3298-7076

OpenAlex ID: A5025234672

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

2026 · Martin Wermke, Sebastian Ochsenreither, et al. · Nature Medicine · 8

1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation

2024 · M. Wermke, S. Ochsenreither, et al. · Annals of Oncology · 4

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

2026 · Martin Wermke, Sebastian Ochsenreither, et al. · Nature Medicine · 1

First-in-human results with IMA401, a MAGEA4/8-targeted T-cell receptor–based bispecific T-cell engager (TCER) in recurrent or refractory solid tumors.

2026 · Martin Wermke, Dirk Jaeger, et al. · Journal of Clinical Oncology

Works count: 4

Citation count: 13

H-index: 2

I10-index: